Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Enzastaurin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 14 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 15 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 06 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.